SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-077391
Filing Date
2024-06-25
Accepted
2024-06-25 17:00:04
Documents
2
Period of Report
2024-06-21

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 8771
2 EX-24.LISTERPOA verv-ex24_listerpoa.htm EX-24.LISTERPOA 11112
  Complete submission text file 0000950170-24-077391.txt   21350
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215
Business Address
Lister Troy (Reporting) CIK: 0002023489 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40489 | Film No.: 241069727